Core Viewpoint - The approval of the innovative drug Rilaforp α injection by the National Medical Products Administration marks a significant advancement in the treatment of advanced gastric cancer, addressing a critical need in the market [1] Company Summary - The company, through its subsidiary Suzhou Shengdiya Biopharmaceutical Co., Ltd., has developed Rilaforp α injection, a dual-function fusion protein targeting PD-L1 and TGF-βRII, which is expected to improve treatment outcomes for patients with advanced gastric cancer [1] - The total research and development investment for the Rilaforp α injection project has reached approximately 71.13 million yuan [1] Industry Summary - Gastric cancer has nearly one million new cases globally each year, with over 655,000 deaths, highlighting the severity of the disease and the urgent need for effective treatment options [1] - Current immunotherapy options, particularly immune checkpoint inhibitors, have shown limited long-term survival benefits for patients, especially those with liver metastases, indicating a gap in the market for innovative therapies [1]

Core Insights - 博锐生物 is preparing for an IPO on the Hong Kong Stock Exchange, showing consistent revenue growth in recent years but a declining gross margin [1] Financial Performance - Revenue for 2023 and 2024 is projected at 1.257 billion and 1.623 billion respectively, with operating profits of 61.65 million and 158 million, and net profits of 19.01 million and 91.3 million [1] - For the first nine months of 2025, revenue reached 1.379 billion with a net profit of 122 million [1] - Gross margins have declined from 82.2% in 2023 to 74.4% in the first nine months of 2025, a total decrease of 7.8 percentage points [1] - Adjusted net margins have increased from 2.5% in 2023 to 11.3% in the first nine months of 2025, indicating effective cost control and expense management [2] Customer and Supplier Concentration - The company has a high customer concentration, with revenue from the top five customers accounting for over 60% of total revenue in recent years [2][3] - The largest customer contributed 28.2%, 32.3%, and 27.7% of revenue in 2023, 2024, and the first nine months of 2025 respectively [2] - Supplier concentration is also high, with the top five suppliers accounting for 30.4%, 34.1%, and 46.0% of total purchases in the same periods [3] Related Party Transactions - 博锐生物 has multiple related party transactions with its controlling shareholder, 海正药业, including asset leasing and technical services, with rental expenses of 2.8 million and 3.2 million for 2023 and 2024 respectively [2] - The company has applied for and received a three-year exemption from the Hong Kong Stock Exchange regarding certain related party transaction approvals [2]

Company Overview - 博锐生物 has submitted a listing application to the Hong Kong Stock Exchange, with Huatai International and JPMorgan serving as joint sponsors [1] - The company is a leading integrated biopharmaceutical firm in China, focusing on comprehensive immunotherapy solutions for autoimmune and inflammatory diseases, as well as tumor immunology [1] - 博锐生物 ranks first among Chinese pharmaceutical companies in revenue from biologics for autoimmune diseases for two consecutive years starting in 2023, according to Frost & Sullivan [1] - The company has eight commercialized products and is transitioning from a proven molecule development enterprise to an innovation-driven biopharmaceutical company, including the development of ADC candidates [1] Industry Insights - The autoimmune disease market is one of the fastest-growing pharmaceutical sectors globally, with blockbuster drugs like Dupilumab, Risankizumab, and Ustekinumab each generating over $10 billion in revenue in 2024 [1] - In China, the market size for autoimmune diseases is projected to grow from RMB 17.4 billion in 2020 to RMB 32.8 billion in 2024, and is expected to reach RMB 289.9 billion by 2035, with a compound annual growth rate (CAGR) of 21.9% [1] - The market share of biologics is rapidly expanding, increasing from RMB 4.2 billion in 2020 to RMB 17.1 billion in 2024, and is anticipated to reach RMB 212.6 billion by 2035 [1] Tumor Immunology Market - Tumor immunology is a cornerstone of modern cancer treatment, utilizing the immune system to identify and eliminate cancer cells, encompassing cell immunotherapy, cytokines, cancer vaccines, and antibody therapies [2] - The success of immune checkpoint inhibitors has transformed the landscape of tumor treatment [2] - The proportion of tumor immunotherapy drugs in the overall oncology drug market in China is expected to grow from 11.3% in 2024 to 47.5% by 2035 [2] - The market size for tumor immunotherapy drugs in China is projected to increase from RMB 14.8 billion in 2020 to RMB 29.3 billion in 2024, and further expand to RMB 495.4 billion by 2035 [2]

Investment Rating - The report does not explicitly state an investment rating for the biopharmaceutical industry or Fitinib specifically Core Insights - The biopharmaceutical innovation market in China is experiencing significant developments, particularly in the context of Fitinib, with a focus on market trends, sales dynamics, and competitive landscape [4][6][28] - The Hong Kong innovation drug sector has shown strong performance, with the Hang Seng Innovation Drug Index rising approximately 18% in July 2025, significantly outperforming the A-share market [6] - The A-share innovation drug sector is also on an upward trend, with notable advancements in tumor immunotherapy and neurodegenerative disease drugs [6] - Fitinib's sales volume and revenue have shown fluctuations, with a notable decline in July 2025, indicating market pressures and competitive challenges [7][14] Sales Dynamics - Fitinib's sales volume in China has been volatile, with 1mg and 5mg specifications experiencing fluctuations and overall growth stagnation or decline as of July 2025 [7][9] - In July 2025, the sales volume for 1mg was 13,053 boxes, down 7.9% from the previous month, while the 5mg specification saw a slight decline to 5,319 boxes [8][9] - Year-over-year sales trends from July 2020 to July 2025 show that 1mg sales increased by 156.0% in 2021 but have since plateaued, with a slight decline of 0.4% in 2025 [10][21] Revenue Dynamics - The sales revenue for Fitinib's 1mg and 5mg specifications also declined in July 2025, reflecting intense market competition and policy adjustments [14][16] - The 1mg specification's revenue was 2,461.0 million yuan in July 2025, down 7.9%, while the 5mg specification's revenue was 1,336.3 million yuan, down 0.7% [15][16] - Historical revenue data indicates that the 1mg specification had a consistent growth trend until 2025, where it experienced a decline, while the 5mg specification has shown a continuous downward trend since 2023 [17][21] Generic Drug Dynamics - As of July 2025, the first generic application for Fitinib by Zhengda Tianqing Pharmaceutical has been accepted, positioning the company to potentially capture market share as the original patent expires [22][27] - The core compound patent for Fitinib is expected to expire in May 2028, with additional patent challenges that may allow generics to enter the market sooner [27][22] New Drug Development Trends - The report highlights significant advancements in small molecule targeted therapies for colorectal cancer, with multiple companies making progress in new drug development [28][31] - Notable developments include FDA approvals for new combination therapies that provide additional treatment options for patients with specific mutations in colorectal cancer [28][31][35]

Core Viewpoint - TheraVectys SA, a French biotech company, is considering an IPO in Hong Kong, potentially raising several hundred million dollars, with plans to proceed as early as this year [1] Company Overview - TheraVectys is an immunotherapy company primarily operating in France and the United States, focusing on the development of lentiviral vectors for the prevention and treatment of cancer and other diseases [1] - The company was spun off from the Pasteur Institute and has backing from Tethys Invest SAS [1] Industry Context - Foreign biotech companies typically opt for listings in Europe or the United States, making a Hong Kong IPO a rare move for non-Chinese biotech firms [1] - China is challenging Western dominance in medical innovation, reshaping the biotech industry landscape [1] - In the previous year, healthcare companies raised approximately $13 billion in the Hong Kong stock market [1]

Core Insights - The approval of the anti-CTLA-4 monoclonal antibody Daberxin® (Ipilimumab N01 injection) by the National Medical Products Administration (NMPA) marks it as the first domestically developed anti-CTLA-4 inhibitor approved in China, providing a significant breakthrough in neoadjuvant treatment for resectable IIB-III stage microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colorectal cancer patients [2][3] Group 1: Drug Approval and Clinical Impact - Daberxin® is now part of the first "dual immunotherapy" neoadjuvant treatment regimen approved globally for this indication, which is expected to change clinical practices and fill a gap in the neoadjuvant treatment landscape for colorectal cancer [2][3] - In a phase III registration study (NeoShot-III), 82% of the first 50 patients treated with the "dual immunotherapy" showed no residual tumors in surgical specimens, achieving pathological complete response (pCR), with no additional safety risks compared to direct surgery [3] Group 2: Company Development and Market Position - As of now, the company has successfully launched 7 innovative drugs by 2025, with a focus on oncology, metabolism, autoimmune diseases, and ophthalmology, indicating a robust pipeline and commercialization strategy [4] - The company is transitioning from a single-focus on oncology to a dual-drive model that includes chronic diseases, aiming to establish a comprehensive commercialization platform in this area [4] - With the ongoing launch of new chronic disease products and stable contributions from core oncology products, the company's goal of exceeding 20 billion yuan in product revenue by 2027 is becoming increasingly realistic [4][5]

Core Viewpoint - The study reveals a novel immune evasion mechanism in melanoma, where melanoma cells release melanosomes that mimic tumor antigens, leading to T cell exhaustion and impaired immune response [2][3]. Group 1: Immune Evasion Mechanism - Melanoma cells secrete melanosomes that are decorated with MHC molecules, which stimulate CD8+ T cells, causing their exhaustion and apoptosis [2][3]. - The presence of melanosomes allows melanoma cells to effectively evade immune detection by misleading T cells [3]. Group 2: Research Findings - Analysis of 69 melanoma patient samples showed that non-responders to immunotherapy had significantly more T cells with pigment deposits, indicating a state of exhaustion [6]. - Melanosomes, previously thought to only transport skin pigment, were found to be rich in immune-related proteins, including MHC molecules loaded with tumor-associated antigens [9]. Group 3: Mechanism of T Cell Exhaustion - T cells that mistakenly recognize melanosomes as tumor cells undergo incomplete activation, leading to mitochondrial dysfunction and eventual apoptosis [10][11]. - This mechanism results in T cells being unable to fully activate or rest, creating a state of cognitive confusion [10][11]. Group 4: Therapeutic Implications - Inhibition of melanosome secretion using a known tyrosinase inhibitor, such as kojic acid, significantly increased CD8+ T cell infiltration and suppressed tumor growth in melanoma models [12]. - The study suggests that targeting melanosome biogenesis or secretion pathways could enhance the efficacy of existing immune checkpoint inhibitors [14][16]. Group 5: Future Directions - Combining melanosome secretion inhibitors with anti-PD-1 antibodies may provide new hope for patients unresponsive to current immunotherapies [16]. - The findings could also influence CAR-T cell therapies by removing T cell clones sensitive to melanosomes before reinfusion, potentially improving treatment outcomes [17].

Core Insights - The "People's Good Doctor Jinshan Camellia Plan" conference highlighted advancements in cancer prevention and control, focusing on high-quality development in the field [1] Group 1: Cancer Treatment Advances - Hepatobiliary tumor treatment has entered an immune-dominant phase, significantly extending patient survival and creating curative opportunities for inoperable tumors [1] - Lung cancer patients have seen improved survival rates due to the promotion of precision diagnosis and treatment, with breakthroughs in small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) [2] - Innovative drugs and treatment strategies in esophageal and gastric cancers have led to significant clinical advancements, although challenges in standardization and precision screening remain [2] Group 2: Multidisciplinary Collaboration - A multidisciplinary collaboration model is becoming mainstream in cancer treatment, allowing for personalized treatment plans through joint consultations among various specialists [4] - There is a need for improved management of patient follow-ups and a more balanced regional development in cancer prevention and treatment [4] Group 3: Emerging Treatment Modalities - Immunotherapy combined with chemotherapy has become a first-line treatment for advanced nasopharyngeal carcinoma, with ongoing exploration of different intervention models [3] - The application of CAR-T cell therapy and targeted drugs has provided long-term survival opportunities for previously hard-to-treat hematological cancer patients [3] Group 4: Future Directions - Continuous innovation in clinical research and acceleration of new treatment technologies are essential for enhancing cancer prevention and treatment systems [5] - The focus should be on early screening, diagnosis, and treatment management to provide patients with better survival prospects [5]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Shanghai Henlius Biotech, Inc. 上海復宏漢霖生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2696） 自願公告 HLX18是本公司自主研發的納武利尤單抗生物類似藥，潛在適應症包括黑色 素瘤、非小細胞肺癌、惡性胸膜間皮瘤、腎細胞癌、經典型霍奇金淋巴瘤、 頭頸部鱗狀細胞癌、尿路上皮癌、胃癌、胃食管連接部癌或食管腺癌、食管 癌、結直腸癌、肝細胞癌等原研藥已獲批的適應症。T細胞中表達的PD-1受 體與其配體PD-L1和PD-L2結合，可以抑制T細胞增殖和細胞因子生成。部 分腫瘤細胞的PD-1配體上調，通過這個通路信號傳導可抑制激活的T細胞對 腫瘤的免疫監視。納武利尤單抗是一種人類免疫球蛋白G4(IgG4)單克隆抗體 (HuMAb)，可與PD-1受體結合，阻斷其與PD-L1和PD-L2之間的相互作用， 阻斷PD1通路介導的免疫抑制反應，包括抗腫瘤免疫反應 ...

Group 1 - The core viewpoint of the news is that Yiming Biotech-B (01541) has made significant progress in the development of innovative drugs for autoimmune diseases, with the acceptance of the clinical trial application for its dual-target antibody IMM0306S by the National Medical Products Administration (NMPA) [1] - IMM0306S is a subcutaneous formulation developed based on Yiming Biotech's core product, IMM0306, which is the world's first clinical-stage dual-target specific molecule targeting CD47 and CD20, developed using the company's "mAb-Trap" technology platform [1] - The stock price of Yiming Biotech-B increased nearly 4%, with a current price of 6.23 HKD and a trading volume of 3.1192 million HKD [1] Group 2 - At the 67th American Society of Hematology (ASH) annual meeting, Yiming Biotech presented data from a Phase I/II clinical study of IMM0306 combined with lenalidomide for the treatment of relapsed/refractory CD20-positive follicular lymphoma, showing an objective response rate (ORR) of 91.2% and a complete response (CR) rate of 67.6% in patients who had failed at least one line of anti-CD20 monoclonal antibody treatment [2] - The safety profile of the combination therapy is manageable, with no risk of cytokine storm, providing a promising new immunotherapy strategy for this currently incurable disease with limited treatment options after relapse [2]